Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children

What Was Tested

The paper reports a study of GHRH (Growth Hormone-Releasing Hormone) and Sermorelin, published as a randomized controlled trial.

OBJECTIVE The aim of the study was to investigate whether pyridostigmine, a cholinesterase inhibitor which is thought to act at the hypothalamus to inhibit somatostatin secretion, would augment spontaneous or GHRH-stimulated serum GH levels in patients with GH-insufficiency.

Why It Was Studied

Studies were performed during the daytime (0900-1800 h) in five patients, and the night-time (2100-0600 h) in a further five.

MEASURES Blood for serum GH was sampled every 20 min, and analysed using the PULSAR program.

Who Took Part

PubMed indexes the participants as children, both men and women.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

The participants were allocated by chance, so the GHRH (Growth Hormone-Releasing Hormone) group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether GHRH (Growth Hormone-Releasing Hormone) was given.

A placebo (an inactive look-alike) gave the GHRH (Growth Hormone-Releasing Hormone) group a baseline to be compared against.

What Was Measured

MEASURES Blood for serum GH was sampled every 20 min, and analysed using the PULSAR program.

PubMed files the paper under topics including Abdominal Pain, Computers, Growth Disorders, Growth Hormone, Growth Hormone-Releasing Hormone and Pyridostigmine Bromide.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) and Sermorelin.

The publication is from 1991 (Clinical endocrinology), a journal based in England.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page and the Sermorelin compound page, all human trials.